Literature DB >> 18356457

Nephrogenic systemic fibrosis: possible association with a predisposing infection.

Lauren Parks Golding1, James M Provenzale.   

Abstract

OBJECTIVE: Infection at time of MR contrast administration has been reported to predispose patients with renal failure to development of nephrogenic systemic fibrosis (NSF). We assessed the frequency of infection at the time of MR contrast administration in a group of NSF patients.
MATERIALS AND METHODS: Eight patients developed NSF during 2002-2006, of whom seven received the MR contrast agent gadodiamide (Omniscan), with doses of 0.10-0.31 mmol/kg. Data for the following were available for only 2005 and 2006: numbers of infected and uninfected renal failure patients who received MR contrast material and number of contrast-enhanced MR scans in all patients. We extrapolated data to 2002-2006 to approximate rates of NSF in infected and uninfected renal failure patients using Fisher's exact test for association between variables and calculated odds ratios with 95% CIs.
RESULTS: Five of seven NSF patients receiving MR contrast material had infections at the time of contrast administration. Three hundred thirty-four patients with renal failure received MR contrast material in 2005 and 2006 (29 infected). The rate of NSF was 6.7% in infected renal failure patients and 0.26% in uninfected patients. Data extrapolated to 2002-2006 yielded estimates of 75 infected and 750 uninfected renal failure patients. The association of NSF with infection was highly significant (p < 0.001) with an odds ratio of 25 and CI of 3.9-264.4.
CONCLUSION: The association of NSF with infection was highly significant, supporting the hypothesis that infection at the time of MR contrast administration in renal failure patients predisposes to NSF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18356457     DOI: 10.2214/AJR.07.2884

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

Review 1.  Nephrogenic systemic fibrosis in liver disease: a systematic review.

Authors:  Sameer M Mazhar; Masoud Shiehmorteza; Chad A Kohl; Michael S Middleton; Claude B Sirlin
Journal:  J Magn Reson Imaging       Date:  2009-12       Impact factor: 4.813

2.  Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey.

Authors:  Lisa B Nachtigall; Niki Karavitaki; Katja Kiseljak-Vassiliades; Luma Ghalib; Hidenori Fukuoka; Luis V Syro; Daniel Kelly; Maria Fleseriu
Journal:  Pituitary       Date:  2019-02       Impact factor: 4.107

Review 3.  Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance.

Authors:  Theresa Reiter; Oliver Ritter; Martin R Prince; Peter Nordbeck; Christoph Wanner; Eike Nagel; Wolfgang Rudolf Bauer
Journal:  J Cardiovasc Magn Reson       Date:  2012-05-20       Impact factor: 5.364

4.  Erythema nodosum masking nephrogenic systemic fibrosis as initial skin manifestation.

Authors:  Kar Wah Fuah; Christopher Thiam Seong Lim
Journal:  BMC Nephrol       Date:  2017-07-24       Impact factor: 2.388

5.  Understanding nephrogenic systemic fibrosis.

Authors:  Tushar Chopra; Kiran Kandukurti; Silvi Shah; Raheel Ahmed; Mandip Panesar
Journal:  Int J Nephrol       Date:  2012-11-04

Review 6.  Nephrogenic Systemic Fibrosis as a Complication after Gadolinium-Containing Contrast Agents: A Rapid Review.

Authors:  Sandra Lange; Wioletta Mędrzycka-Dąbrowska; Katarzyna Zorena; Sebastian Dąbrowski; Daniel Ślęzak; Anna Malecka-Dubiela; Przemysław Rutkowski
Journal:  Int J Environ Res Public Health       Date:  2021-03-15       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.